Mesothelioma Treatment Combines Proton and Photodynamic Therapy

Intraoperative photodynamic therapy combined with novel proton radiation improved survival time significantly for recent patients with advanced-stage pleural mesothelioma. The study — the first to measure the impact of this combination — involved 10 consecutive patients treated at the University of Pennsylvania’s Abramson Cancer Center. The treatment regimen resulted in a 90 percent, two-year disease control rate and an impressive 30.3-month median overall survival from the time of diagnosis. All 10 patients were diagnosed before treatment began with stage 3 or stage 4 disease, which typically results in a 10 to 14-month survival. “The combination may have worked synergistically to better fight the cancer,” Dr. Charles Simone, senior study author, told The Mesothelioma Center at Asbestos.com. “Results were impressive…with better than expected clinical outcomes.” Simone Bringing Proton Therapy to New York Simone has pioneered the use of proton therapy for mesothelioma. He was recently named chief medical officer at the New York Proton Center, which opens in May as the first facility in the state to offer this type of radiation therapy. The journal Photochemistry and Photobiology published the study in January 2019. Simone, previously the medical director at the University of Maryland School of Medicine, was joined by doctors from the Perelman School of Medicine at the University of Pennsylvania and The UCSF Helen Diller Famil...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news

Related Links:

Rare thoracic malignancies, those with an incidence lower than 6 per 100,000 as a threshold of rarity, include epithelial tumors of the trachea, thymus and malignant pleural mesothelioma (MPM). Foremost among these rare tumors is mesothelioma, accounting for 2.1 cases per 100,000 people per year [1]. While we are witnessing years of exciting progress for lung cancer patients, very few advances have been made in MPM since the approval of pemetrexed in 2004 [2]. Not surprisingly, life expectancy of MPM remains suboptimal with a median overall survival (OS) of less than 1  year and 5-year OS of approximately 5% [1].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
in Collins Andrew Churg Well-differentiated papillary mesothelioma (WDPM) is an uncommon mesothelial proliferation that is most commonly encountered as an incidental finding in the peritoneal cavity. There is controversy in the literature about whether WDPM is a neoplasm or a reactive process and, if neoplastic, whether it is a variant or precursor of epithelial malignant mesothelioma or is a different entity. Using whole exome sequencing of five WDPMs of the peritoneum, we have identified distinct mutations in EHD1, ATM, FBXO10, SH2D2A, CDH5, MAGED1, and TP73 shared by WDPM cases but not reported in malignant mesoth...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
In conclusion, our study has identified that acidic mesothelioma milieu drives DC dysfunction and altered T cell response through pharmacologically reversible TGF-β2-dependent mechanisms.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Abstract BRCA1-associated protein 1 (BAP1) is a deubiquitinating enzyme that has long been considered to be a tumor suppressor in various tumors, including renal cell carcinoma, uveal melanoma, mesothelioma, and cutaneous melanoma. However, the involvement of BAP1 in the progression of prostate cancer has not been studied until recently. Herein, we investigated the tumor promoting function of BAP1 in the context of prostate cancer. Analysis of The Cancer Genome Atlas (TCGA) data set showed that prostate cancer patients express high levels of BAP1 mRNA. High BAP1 expression is inversely correlated with disease-free survival...
Source: Genetics and Molecular Biology - Category: Genetics & Stem Cells Source Type: research
Abstract Malignant mesothelioma (MM) is an aggressive asbestos-related cancer of the serous membranes. Despite intensive treatment regimens, MM is still a fatal disease, mainly due to the intrinsic resistance to current therapies and the lack of predictive markers and new valuable molecular targets. Protein arginine methyltransferase 5 (PRMT5) inhibition has recently emerged as a potential therapy against methylthioadenosine phosphorylase (MTAP)-deficient cancers, in which the accumulation of the substrate 5'-methylthioadenosine (MTA) inhibits PRMT5 activity, thus sensitizing the cells to further PRMT5 inhibition....
Source: J Cell Mol Med - Category: Molecular Biology Authors: Tags: J Cell Mol Med Source Type: research
livier Coqueret Catherine Guette Daniel L. Pouliquen Recent findings suggest that S100A4, a protein involved in communication between stromal cells and cancer cells, could be more involved than previously expected in cancer invasiveness. To investigate its cumulative value in the multistep process of the pathogenesis of malignant mesothelioma (MM), SWATH-MS (sequential window acquisition of all theoretical fragmentation spectra), an advanced and robust technique of quantitative proteomics, was used to analyze a collection of 26 preneoplastic and neoplastic rat mesothelial cell lines and models of MM with increasing...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
This study of women included 275 cases of pleural mesothelioma and 79 cases of peritoneal. Papillary mesothelioma and localized mesothelioma cases were excluded. Previous reports have shown that 22% to 29% of mesothelioma cases involve women, but only 12% in this particular study. Other Notable Takeaways The majority of those studied were exposed to asbestos through household contact. Women who worked in occupations and industries associated with higher asbestos exposure had objective markers of exposure similar to men. Survival was longer for the epithelial subtype of mesothelioma and magnified with the per...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Publication date: Available online 10 January 2020Source: Pathology - Research and PracticeAuthor(s): Masanori Matsuda, Hironori Ninomiya, Ryo Wakejima, Kentaro Inamura, Sakae Okumura, Mingyon Mun, Masanobu Kitagawa, Yuichi IshikawaAbstractCalretinin, a mesothelioma marker, is sometimes expressed in lung cancer, which may complicate the differential diagnosis of mesothelioma. Here, the clinicopathological and immunohistochemical characteristics of calretinin-positive lung cancer were examined to reduce confusion with malignant mesothelioma. Calretinin expression in 307 consecutive cases of lung cancer was evaluated immunoh...
Source: Pathology Research and Practice - Category: Pathology Source Type: research
CONCLUSIONS.—: Highlighted by their relevance in the large cohort reported, we recommend 2 useful panels to the differential diagnosis at 10% cutoff. PMID: 31389715 [PubMed - as supplied by publisher]
Source: Archives of Pathology and Laboratory Medicine - Category: Laboratory Medicine Authors: Tags: Arch Pathol Lab Med Source Type: research
The Princess Margaret Cancer Center in Toronto has moved from SMART to SMARTER with the recent launch of its latest clinical trial for pleural mesothelioma patients. SMARTER is the acronym for Surgery for Mesothelioma After Radiation Therapy using Extensive pleural Resection, which also describes the latest clinical trial. The phase I clinical trial is an unconventional approach to treatment of mesothelioma: Find the maximum tolerated dosage of hypofractionated radiation to stimulate the immune system before aggressive surgery. It comes on the heels of the SMART protocol, which stands for Surgery for Mesothelioma After Rad...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
More News: Asbestosis | Cancer | Cancer & Oncology | Chemotherapy | Environmental Health | Epithelial Cancer | Immunotherapy | Intensity-Modulated Radiation Therapy | Mesothelioma | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Radiation Therapy | Neoadjuvant Therapy | Proton Therapy | Radiation Therapy | Study | Toxicology | University of Maryland | University of Pennsylvania